| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
112.14(B) |
| Last
Volume: |
521,646 |
Avg
Vol: |
759,686 |
| 52
Week Range: |
$692.45 - $1045.37 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
45 |
67 |
128 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sing George L |
Director |
– • – |
2020-08-20 |
4 |
S |
$615.48 |
$12,955,042 |
D/D |
(21,000) |
104,415 |
|
22% |
|
| Sing George L |
Director |
– • – |
2020-08-20 |
4 |
OE |
$57.11 |
$571,100 |
D/D |
10,000 |
114,415 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2020-08-11 |
4 |
AS |
$594.20 |
$20,174,355 |
I/I |
(33,460) |
50,192 |
|
-18% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-08-04 |
4 |
AS |
$654.46 |
$455,504 |
D/D |
(696) |
23,973 |
|
-24% |
|
| Ryan Arthur F |
Director |
– • – |
2020-08-03 |
4 |
AS |
$633.78 |
$64,193 |
D/D |
(100) |
28,543 |
|
-22% |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-07-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
57,465 |
0 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-07-21 |
4 |
AS |
$636.56 |
$2,381,317 |
D/D |
(3,709) |
17,501 |
|
-20% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-21 |
4 |
AS |
$647.50 |
$253,204 |
D/D |
(391) |
24,669 |
|
-20% |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-07-20 |
4 |
OE |
$52.03 |
$1,907,015 |
D/D |
12,224 |
21,210 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-07-20 |
4 |
D |
$655.57 |
$4,124,191 |
D/D |
(6,291) |
18,986 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-20 |
4 |
D |
$655.57 |
$4,859,740 |
D/D |
(7,413) |
25,060 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-20 |
4 |
OE |
$399.66 |
$4,177,160 |
D/D |
8,500 |
29,671 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-07-14 |
4 |
AS |
$614.62 |
$2,451,277 |
D/D |
(3,929) |
44,331 |
|
-18% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-07-14 |
4 |
AS |
$630.77 |
$1,507,677 |
D/D |
(2,380) |
41,951 |
|
-18% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-14 |
4 |
AS |
$640.50 |
$370,850 |
D/D |
(579) |
23,973 |
|
-18% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-07-13 |
4 |
D |
$623.98 |
$4,175,050 |
D/D |
(6,691) |
48,260 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-07-13 |
4 |
OE |
$30.63 |
$398,190 |
D/D |
13,000 |
54,951 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-07-13 |
4 |
AS |
$620.64 |
$5,028,022 |
D/D |
(8,000) |
41,951 |
|
-16% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-08 |
4 |
AS |
$634.14 |
$742,011 |
D/D |
(1,160) |
23,973 |
|
-16% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-07 |
4 |
D |
$640.88 |
$7,267,579 |
D/D |
(11,340) |
25,133 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-07-07 |
4 |
OE |
$399.66 |
$6,555,850 |
D/D |
12,500 |
27,152 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-07-07 |
4 |
AS |
$650.00 |
$1,108,900 |
D/D |
(1,706) |
643 |
|
-13% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-07-07 |
4 |
OE |
$391.92 |
$668,616 |
D/D |
1,706 |
2,349 |
|
- |
|
| Sing George L |
Director |
– • – |
2020-07-07 |
4 |
AS |
$650.00 |
$1,950,474 |
I/I |
(3,000) |
4,700 |
|
-13% |
|
| Sing George L |
Director |
– • – |
2020-07-07 |
4 |
AS |
$650.00 |
$4,875,000 |
D/D |
(7,500) |
115,415 |
|
-13% |
|
2430 Records found
|
|
Page 28 of 98 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
7.30 (0.69%) 
